<?xml version="1.0" encoding="UTF-8"?>
<p id="Par30">A prospective meta-analysis of clinical trials of critically ill patients with COVID-19 showed that administration of systemic corticosteroids, compared with usual care or placebo, was associated with lower 28-day all-cause mortality [
 <xref ref-type="bibr" rid="CR69">69</xref>]. Nowadays, According to China’s New Coronavirus Pneumonia Diagnosis and Treatment Plan (Trial Version 8), the patients with progressive deterioration of oxygenation indicators, rapid imaging progress, and excessive activation of the body’s inflammatory response, glucocorticoids should be used in a short period of time. The recommended dose is equivalent to 0.5 ~ 1 mg/kg/day of methylprednisolone, Meantime, WHO also made a strong recommendation for use of corticosteroids in severe and critical covid-19 because there is a lower risk of death among people treated with systemic corticosteroids [
 <xref ref-type="bibr" rid="CR70">70</xref>].
</p>
